Skip to main content
. 2006 Sep 14;116(10):2663–2672. doi: 10.1172/JCI28773

Figure 1. AR113Q males are smaller and weaker than WT littermates.

Figure 1

(A) Body mass (mean ± SD) reported by age of WT (red line, n = 9), AR113Q (blue line, n = 5–22 depending on age, due to early death), and castrated AR113Q males (C-AR113Q) (green line, n = 9). AR113Q males were significantly smaller than WT (P < 0.001), and castration further decreased body mass (P < 0.05 by ANOVA with the Neuman-Keuls multiple comparison test). Inset shows body mass of AR48Q (n = 7) and WT (n = 5) males at 22–23 months (P > 0.05 by unpaired Student’s t test). (B) Forelimb grip strength (mean ± SD) of WT (red line, n = 13), AR113Q (blue line, n = 5), and castrated AR113Q males (green line, n = 9) evaluated monthly beginning at 11–13 months. The 3 curves are significantly different from each other (P < 0.001 by ANOVA with the Neuman-Keuls multiple comparison test). Implantation of testosterone pellets into castrated AR113Q males at 17–19 months is indicated by arrow. Inset shows grip strength of AR48Q (n = 7) and WT (n = 5) males at 22–23 months (P > 0.05 by unpaired Student’s t test).